Eli Lilly and Co
FDA approves Eli Lilly’s tirzepatide for weight loss, paving way for wider use of blockbuster drug
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, on March 29, 2023. George Frey | Reuters The Food and Drug Administration on Wednesday approved Eli Lilly‘s blockbuster drug tirzepatide for weight loss, paving the way for […]
Read More
The Ozempic effect has battered this weight loss stock, but Morgan Stanley says it’s a top pick
Game-changing anti-obesity medications have posed nothing short of an existential crisis for Weight Watchers parent WW International since they arrived on the scene, but CEO Sima Sistani has been confronting this challenge head-on. Despite an 11% dive in the stock Friday, Morgan Stanley said it thinks the company “has gone through an incredible transformation over […]
Read More
Stocks building the biggest moves midday: Starbucks, Roku, Eli Lilly, Affirm and more
Check out out the firms creating headlines in midday buying and selling. Starbucks — Shares jumped much more than 10% immediately after the business posted an earnings and income conquer in the fiscal fourth quarter. Administration also described far better-than-anticipated general performance in China, its second-biggest sector. Roku — The streaming online video platform rallied […]
Read More
Eli Lilly says supply of blockbuster diabetes drug Mounjaro has improved in U.S.
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, March 29, 2023. George Frey | Reuters Eli Lilly on Thursday said supply of its blockbuster diabetes drug Mounjaro has improved in the U.S. after months of widespread […]
Read More
Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlook
Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain. Cristina Arias | Cover | Getty Images Eli Lilly on Thursday reported third-quarter revenue and adjusted earnings that topped estimates on strong demand for its diabetes drug Mounjaro, but slashed its full-year profit guidance due to charges primarily related to its recent acquisitions. Here’s […]
Read More
Inventory futures are very little modified as notice turns from Fed to latest earnings studies: Are living updates
Spencer Platt | Getty Photos Inventory futures are around flat Wednesday night as buyers shifted emphasis from the Federal Reserve’s plan decision to the most recent batch of corporate earnings reports. Futures tied to the Dow Jones Industrial Average slid 4 factors, buying and selling near flat. S&P 500 futures and Nasdaq 100 futures each […]
Read More
Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offs
CFOTO | Future Publishing | Getty Images Pfizer on Tuesday reported a narrower than expected loss for the third quarter as the drugmaker recorded charges largely related to struggles for its Covid antiviral treatment Paxlovid and Covid vaccine. Pfizer said that it recorded a $5.6 billion charge for inventory write-offs in the third quarter due […]
Read More
Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end
Novo Nordisk and Eli Lilly reign over the anti-obesity drug market, and don’t expect this duopoly to end soon, analysts say. But other companies — both big and small — are hoping to grab a piece of this lucrative market. In a research note, Piper Sandler analyst Yasmeen Rahimi said the firm is tracking more […]
Read More
These shares reporting upcoming week ordinarily defeat the Road and rally
Wall Road is bracing for a further chaotic 7 days of earnings as the reporting time period reaches its midway place — and specific shares are most likely to carry out better on the back again of their experiences. Roughly 29% of the S & P 500 is set to report up coming 7 days. […]
Read More
AI, excess weight decline medicine and additional: Portfolio manager names stocks to perform ‘new secular progress themes’
Marketplaces may well be dealing with an “unconventional total” of uncertainty, but there continue to are really fantastic chances ideal, in accordance to a single portfolio supervisor, who tells CNBC Professional about three new expansion spots and the shares he likes. There are numerous “cross currents” in the industry correct now, claimed Sanjay Ayer of […]
Read More